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Aim: In this article the aim is to provide a concise narrative review and inform the institu-
tional experience at a referral center in Chile with the use of radio-chemotherapy in anal
cancer.
Background: Cancer of the anus and anal canal is mainly a loco-regional disease. For years the
standard of care has been concomitant radio-chemotherapy, which permits organ preser-
vation and better local control than alternative surgical procedures.
Materials and methods: A retrospective analysis of 44 patients treated between 2002 and 2010
was performed. Local recurrence, distant recurrence and overall survival were analyzed
with the Kaplan–Meier method. Relevant groups where compared with the log-rank test
and  univariate analysis were done with the Cox proportional hazards model.
Results: Median follow-up of the cohort was 56 months, with a minimum follow-up of at
least 24 months. There was a signiﬁcant difference between clinical stages in disease free
survival (log-rank trend p < 0.001), and a signiﬁcant difference in overall survival (OS) when
comparing clinical stages that were grouped in stage I–IIIa and IIIB (log-rank p = 0.001). On
univariate analysis, age older than 60, having received full treatment and dose above 45 Gy
were all signiﬁcantly related to OS (p < 0.05). An overall survival of 45% and disease free
survival of 45% at 5 years were found in our series.
Conclusions: Our ﬁndings show that results at the Instituto de Radiomedicina in Chile arecomparable to published literature. Dismal results in stage IIIb cases indicate much work
remains in therapies to achieve loco-regional control in locally advanced cases.
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Table 1 – Patient characteristics.
Characteristics No. of patients (%)
Median age (range) 62 (28–63)
Sex
Male 12 (27)
Female 32 (73)
HIV status
Positive 6 (14)
Negative 38 (86)
Histological grade
1 2 (5)
2 22 (50)
3 20 (45)
T stage
1  5 (11)
2 12 (27)
3 14 (32)
4 13 (30)
N stage
0  23 (53)
1 9 (20)
2 12 (27)
Stage (AJCC 2003)
I 6 (14)
II 13 (30)
IIIA 9 (20)
IIIB 16 (36)
Karnofsky score
70 4 (9)reports of practical oncology and 
.  Background
he Chilean Ministry of Health, in its ﬁrst report of pop-
lation cancer registries, estimates an annual incidence of
ectal and anal cancer of 4.4 cases per 100,000 people, with
pproximately 790 new cases diagnosed yearly. The adjusted
eath rate is 4.9 deaths per 100,000 people, with an estimated
umber of 480 annual deaths.1 Disaggregated data of these
iseases do not exist in Chile. Data from the US indicate that
he median age at diagnosis before 2009 was 60 years of age,
ith 51% of them being diagnosed between 45 and 64. Most
f the cases are diagnosed in a localized stage (49%) or with
egional spread (30%), and only 13% have distant metastases at
he time of diagnosis or stage is unknown (8%). Overall 5-year
urvival reaches 65%, varying widely between stages, from 79%
o 30% in localized and metastatic disease, respectively.2,3
The symptoms of anal cancer are not unique and are also
ymptoms of other conditions, such as hemorrhoids. Symp-
oms may include lumps or bumps located near the anus, anal
leeding or bleeding during bowel movements, anal discharge,
ain in or around the anus, itchy sensation around or inside
he anus, change in bowel habits, such as constipation, diar-
hea and thinning of the stools or para-neoplastic syndrome.4
Due to the low frequency of distant metastases at the time
f diagnosis, anal cancer is considered mainly a loco-regional
isease, making concomitant radio-chemotherapy an ideal
rgan and function sparing treatment which has been the
tandard of care for decades, with excellent results even in
ocally advanced tumors. Since the 1980s, many  attempts have
een made to improve loco-regional control and reduce tox-
city, evaluating the role of mitomycin and investigating the
ole of IMRT.
In this article, the objective is to describe the results of
reatment for anal cancer at a large radiation oncology cen-
er in Chile, identifying relevant prognostic factors in these
ohort of patients.
.  Materials  and  methods
he Institute of Radiation Medicine (IRAM) is the largest
rivate radiation oncology center in Chile, and it provides ser-
ices to a large number of patients from the public health
ector, approximately 3000 annually. All treatment decisions
re made in multidisciplinary tumor boards.
Between 2002 and 2010, 44 patients were treated at the
RAM with the diagnosis of cancer of the anal canal. The treat-
ent delivered was concomitant radio-chemotherapy, with
5 Gy in 25 daily fractions and 1000 mg/m2 of 5-FU, days 1–4,
nd 10 mg/m2 of mitomycin, day 1 the 1st and 5th week of
reatment. An AP ﬁeld was used that includes the pelvis, anus
nd inguinal lymph nodes, with the superior border at L5-S1
nd the inferior border including the anus with a 2 cm margin.
ateral borders include the inguinal lymph nodes determined
y bony landmarks. After an initial dose of 30.6 Gy in 17 frac-
ions the superior extent of the ﬁeld is reduced to the bottom of
he sacroiliac joints, completing another 14.4 Gy in 8 fractions.
atients with clinically negative inguinal nodes also have a
eld reduction of this area at 30.6 Gy. According to clinical80 6 (14)
100 34 (77)
response, patients may receive a 9 Gy boost to the primary
tumor. CT planning was standard in all patients.
2.1.  Statistical  analysis
Descriptive statistics for the analysis were proportions, medi-
ans and ranges where appropriate. The Kaplan–Meier method
was used to estimate survival and graph survival curves. Log-
rank tests where used to compare time to event outcomes
between groups. Cox proportional hazards model was used for
univariate analysis, with p < 0.05 considered statistically sig-
niﬁcant. All analyses where done in STATA 12 (College Station,
Texas).
3.  Results
Median follow-up of the cohort was 56 months, with a min-
imum follow-up of at least 24 months. Table 1 shows the
characteristics of this cohort of patients.
A total of 8 patients experienced loco-regional recurrence
after treatment; in 5 of them it was the only site of failure.
Nine patients had a distant failure, 6 of them with only a dis-
tant failure. In total, 14 patients had a recurrence, with 3 of
them having both loco-regional and distant failures. Of the 8
loco-regional failures, 6 occurred in the ﬁrst three years, while
5 of the 6 distant failures occurred in the same period of time.
Median disease free survival (DFS) deﬁned as loco-regional
failure, distant failure or death for the entire population was
50 months. DFS at 3 and 5 years was 60% and 45%, respectively
(Fig. 1).
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Fig. 1 – Kaplan–Meier curves for disease free survival for all
patients.
Fig. 3 – Kaplan–Meier curves for overall survival accordingMedian overall survival (OS) for the entire cohort was 57
months. OS at 3 and 5 years was 66% and 47%, respectively
(Fig. 2). Results are very similar for OS and DFS.
Overall survival by clinical stage at 3 years was 100% for
stage I, 83% for stage II, 64% for stage IIIa and 40% for stage
IIIb. There was a signiﬁcant difference between clinical stages
in DFS (log-rank trend p < 0.001), and a signiﬁcant difference in
OS when comparing clinical stages grouped in I–IIIa with IIIB
(log-rank p = 0.001, Fig. 3). In a univariate analysis, age older
than 60, having received full treatment as speciﬁed above and
dose >45 Gy were all signiﬁcantly related to OS (p < 0.05). The
low number of patients precludes further statistical analysis.
4.  Discussion
Radio-chemotherapy has been a standard of care for nearly 30
years since Norman Nigro ﬁrst published his results in 1974.5
In that article, Nigro showed preliminary data of three patients
treated with preoperative combined modality therapy with
Fig. 2 – Kaplan–Meier curves for overall survival for all
patients.to stage.
such promising results that radio-chemotherapy became a pri-
mary  treatment, leaving surgery to rescue patients who  failed
treatment.
Several trials have compared radio-chemotherapy with
radiation alone, consistently showing better outcomes in the
combined modality treatment arm. In 1984, Bernard Cum-
mings and colleagues published a retrospective report of 30
patients treated with radio-chemotherapy with 5-ﬂuoracil and
mitomycin, and 25 patients treated with radiation alone with
a similar radiation technique.6 Patients were similarly staged
and where broadly comparable. Patients received 30 Gy with
multiple-beam external radiation to the pelvis including the
inguinal nodes, with a dose above 45 Gy to the primary tumor.
Most of the treatment failures were local failures, and radio-
chemotherapy signiﬁcantly improved primary relapse free
survival and colostomy free survival.
In a large study published in 1996 (ACT I) and updated in
2010 with 13 years of follow-up, 585 patients were random-
ized to receive radiotherapy with or without chemotherapy.7
Radiation consisted on 45 Gy to the pelvis with a 15 Gy boost
to the primary with a 6-week break in between. Chemother-
apy included 5-FU and mitomycin. The combined modality
arm had a better 3-year local control (36% vs. 59%), with no
difference in overall survival.
Bartelink similarly compared both treatments in 110
patients with locally advanced anal cancer.8 Also using a 6-
week break after 45 Gy of external beam radiotherapy 5-FU and
mitomycin were added, with and improved 5-year local con-
trol of 68% vs. 50%, colostomy free survival from 40% to 72%
and disease free survival from 43% to 61%. Complete responses
were also improved from 54% to 80%.
Because of the high incidence of hematological toxicity,
several attempts have been made to replace or remove mit-
omycin from the radio-chemotherapy scheme in anal cancer
treatment. Flam and colleagues published RTOG 87-04, a ran-
domized trial comparing radio-chemotherapy with 5-Fu with
or without mitomycin in 310 patients.9 Patients had a biopsy
performed 4–6 weeks after treatment. In patients with resid-
ual disease, a 9 Gy radiation boost was given to the perineum,
inguinal nodes or both. In these patients, another biopsy
was  performed, and in patients with persistent disease an
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bdomino-perineal resection was done 3–4 weeks later. The
isease free survival rate increased from 51% with 5-FU and
adiation to 73% with radiation combined with 5-FU and
itomycin. The colostomy rate decreased from 22% with radi-
tion and 5-FU to 9% with radiation, 5-FU, and mitomycin.
In 2010 the results of a phase III intergroup trial were
eported of 644 patients comparing 5-FU, mitomycin, and radi-
tion to 5-FU, cisplatin, and radiation.10 The substitution of
isplatin for mitomycin did not only failed to improve disease-
ree survival, but colostomy rates were signiﬁcantly higher in
he group randomized to cisplatin. Mitomycin did, however,
ave greater toxicity than cisplatin. The authors concluded
hat mitomycin remained the standard.
Early European trials planned a gap in radiation therapy
fter 45 Gy in order to decrease toxicity while giving a high
ose to the primary. Radiation dose has historically been at
east 45 Gy even in early stages. Studies that have used higher
oses have not shown improved results, but one must note
hat these studies have used split course radiation, which
ould be accountable for the lack of beneﬁt of increased
ose.6–8
Another subject that has not been settled yet, apart from
adiation dose, is the need for elective irradiation of inguinal
odes in patients with clinically N0 disease. Two recent stud-
es have shown beneﬁt of prophylactic inguinal radiotherapy.
ROG 99.02 evaluated patients with T1–T2, N0 anal carci-
oma with no elective radiation of inguinal nodes, treated
ith radio-chemotherapy with 5-FU and mitomycin, with
 44-month follow-up.11 Inguinal failure occurred in 22.5%
f patients, and was isolated in only 12.5%. A retrospec-
ive French study analyzed 208 patients, mostly with T1–T3
umors.12 Of 181 patients with uninvolved nodes at presenta-
ion, 75 received prophylactic radiation to inguinal nodes and
06 did not. Even though patients who received elective radi-
tion of inguinal nodes had on average larger tumors, they
id signiﬁcantly better in terms of inguinal recurrence (2% vs.
6%). Speciﬁcally for T1–T2 tumors, the 5-year inguinal recur-
ence risk when omitting elective radiation of the inguinal
odes was estimated to be as high as 10%. Considering the
bove data, prophylactic radiotherapy of the inguinal nodes
s recommended in T3–T4 tumors and should be consid-
red in patients with earlier stages (T1–T2). Because there
ay be wide variations in the depth of inguinal nodes,
xial imaging should be used to determine the best tech-
ique and proper prescription for prophylactic inguinal node
adiation.
Results of treatment in our cohort of patients, which were
argely HIV negative, are fairly comparable to published clin-
cal trials. Interesting ﬁndings were that age older than 60,
aving received full treatment and dose >45 Gy were all sig-
iﬁcantly related to OS (p < 0.05). Standard of care treatment,
ith the speciﬁc characteristics discussed above, has been an
ffective treatment modality at the IRAM in the management
f anal canal cancer. Treatment modiﬁcations or intensiﬁca-
ions for patients presenting with stage IIIb disease, where
esults are dismal, need to be explored.
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